1 / 1

Measuring the quality of pharmaceutical care for frail elderly with polypharmacy: Study design

Measuring the quality of pharmaceutical care for frail elderly with polypharmacy: Study design. Julie Heeren 1 , Peter Kemper 1 , Gepke Delwel 2 , Lutien Bakker 2 , Martine de Bruijne 1 , Cordula Wagner 1,3 1 EMGO + Institute for Health Care and Research, VU medical Center, Amsterdam

yuri-thompson
Download Presentation

Measuring the quality of pharmaceutical care for frail elderly with polypharmacy: Study design

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Measuring the quality of pharmaceutical care for frail elderly with polypharmacy: Study design Julie Heeren1, Peter Kemper1, Gepke Delwel2, Lutien Bakker2, Martine de Bruijne1, Cordula Wagner1,3 1 EMGO+ Institute for Health Care and Research, VU medical Center, Amsterdam 2 IGZ, The Health Care Inspectorate 3 NIVEL, Netherlands institute for health services research Background Polypharmacy is a severe problem for frail elderly Pharmaceutical care for frail elderly with polypharmacy (≥5 medicines) is frequently associated with medication-related preventable adverse events. Better understanding of the pharmaceutical care for frail elderly with polypharmacy in the Netherlands will facilitate the effective supervision by The Health Care Inspectorate. *H. Merten, 2012: Adverse events in hospitalised older patients (≥65 years). Research questions How is pharmaceutical care for frail elderly with polypharmacy currently carried out? Which risk indicators can be used to supervise pharmaceutical care for frail elderly with polypharmacy? Results A validated instrument with a baseline measurement The results will provide validated measurement instruments to be used for the baseline measurement of pharmaceutical care for frail elderly with polypharmacy in 2013. This and the proposed risk indicators may facilitate the effective supervision on polypharmacy in frail elderly by the Health Care Inspectorate. Results will be described in a report and research article. Methods The design of the study involves four phases over a period of 12 months, starting in April 2013. The phases are: A risk matrix will be constructed to develop a questionnaire for patients and health care professionals. Phase 1: Development questionnaire The questionnaire of phase 1 is conducted with a random sample of health care professionals and patients. In addition, an inventory of initiatives will be made. Phase 2: Baseline measurement Results of phase 1+2 are used to determine structure-, process-, and outcome indicators to facilitate the supervision of pharmaceutical care for frail elderly with polypharmacy. Phase 3: Determination indicators Conclusion This study will provide the first step to measure the effects of supervision on the quality of pharmaceutical care for frail elderly with polypharmacy Phase 4: Report and follow-up In order to conduct the follow-up measurement, the results will be outlined a report and presented in a workshop for the Health Care Inspectorate. Contact details: P.kemper@vumc.nl or M.heeren@vumc.nl www.onderzoekpatientveiligheid.nl This study is conducted within the Academic Collaborative centre of the Health Care Inspectorate (‘AcademischeWerkplaatsToezicht’) http://www.zonmw.nl/nl/programmas/programma-detail/effectief-toezicht VUmc – Sociale geneeskunde Research Center Safety 4 Patients

More Related